Researchers at the University of Pennsylvania Schools of Medicine and Veterinary Medicine have determined a way to pre-screen cancer patients to see if they are suitable candidates for proteasome inhibitors, a promising class of anti-cancer drugs.
Ortho Biotech Products, L.P. revised the label for PROCRIT? (Epoetin alfa), acting upon guidance from the U.S. Food and Drug Administration (FDA) to revise labeling for all drugs within the erythropoiesis-stimulating agent (ESA) class.
The U.S. Food and Drug Administration (FDA) issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
AARP called on Congress to give the Food and Drug Administration (FDA) the authority to approve safe, cost-effective generic versions of often expensive biologic drug therapies.
Novartis announced that the United States has become the first country in the world to approve Tekturna? (aliskiren), the first new type of medicine in more than a decade for treating high blood pressure – a condition estimated to affect nearly one billion people worldwide and still uncontrolled in nearly 70% of patients.
CV Therapeutics, Inc. (NASDAQ: CVTX) announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine. The study did not meet the primary efficacy endpoint.
An estimated 100,000 patients who have heart attacks each year are not eligible for life-saving beta-blocker drug therapy because their heart rates are too low. Beta-blockers improve survival rates up to 30 percent in people who have had heart attacks by helping to regulate the heartbeat.
A new study to be published in an upcoming edition of the Journal of Reproductive Medicine reveals that Pycnogenol, an antioxidant plant extract from the bark of the French maritime pine tree, significantly reduces symptoms of endometriosis by 33 percent.
A new study in the March issue of the journal Cell Metabolism, published by Cell Press, has identified a common link between multiple assaults on the body, including saturated fats, obesity, and certain types of drugs, all of which can lead to insulin resistance. The researchers found that these metabolic stresses lead to an upswing in production of a particular kind of fat molecule, known as ceramide.
Two researchers from the University Hospital and the Center for Applied Medical Research (CIMA) from the University of Navarra have published an article in Nature Cancer Reviews.